Sun Pharma is a top-ranked Indian pharmaceutical firm. The company’s stock has been continuously in the news lately for walking on the thin line of marketplace volatility, governmental regulations, and strategic expansion. As of 11 am on 7 March 2025, Sun Pharma share price reached ₹1,614.90. This is a 0.09% jump when compared to its last close price.
Let’s explore some of the prevailing trends and key financials impacting Sun Pharma share price today.
Sun Pharma stock has had mixed returns in the last year. While the company has had a modest one-year return of 1.23%, it has had impressive growth over longer terms, with a three-year return of 88.8% and a five-year return of 327.26%. The last few months have been tough, though, with the stock dipping 10.57% over the last three months. This fall is partly due to general market volatility and certain sectoral issues, such as tariff issues and regulatory pressures.
The beta of 0.59 shows relatively stable performance compared to the overall market. It means that Sun Pharma's shares are less volatile than most other stocks. The 52-week high of ₹1,960.35 and low of ₹1,377.20 show the stock's volatility over the last year. Thus, both reflect investor optimism and caution.
Sun Pharma has demonstrated robust financial performance, with a net profit increase of 15.04% in the third quarter of FY2024-2025 compared to the same period last year. The company's earnings per share (EPS) have shown a significant increase, reaching ₹40.21 in 2024 from ₹17.45 in 2020. This growth is supported by a strong return on equity (ROE) of 12.05% and a return on assets (ROA) of 22.86%.
The debt-free nature of the company and its consistent 23.4% CAGR growth in profits over the last five years show strength. Sun Pharma's resilience and effective management, as evident in its retention of profitability despite facing difficult market conditions, boost investor confidence.
Analysts are mostly bullish on Sun Pharma, with a consensus target price of ₹2,076.97, indicating a potential appreciation of around 28.72% from the current price. This is evident in the strong buy ratings by various analysts, including JM Financial, which has a target price of ₹2,115.
The pharma industry is grappling with challenges such as US tariff pressures and regulatory obstacles. Even so, Sun Pharma is optimistic about its growth drivers, backed by its diversified portfolio of products and strategic alliances.
Sun Pharma provides a dividend yield of 0.84%, giving investors a constant flow of income. The latest dividend announcement of ₹10.50 per share by the company also reflects confidence among investors. Foreign institutional investors have upgraded their holdings, reflecting increased interest in the stock.
Sun Pharma's shares provide an interesting combination of stability, growth prospects, and dividend yield and thus make a good bet for investors who want exposure to the pharma space. Investors must keep an eye on overall market trends and industry-specific issues that may affect the stock's performance in the future.